Zeolites with Divalent Ions as Carriers in the Delivery of Epigallocatechin Gallate

Epigallocatechin gallate (EGCG) is a compound with veryhigh therapeuticpotential in the treatment of osteoporosis and cancer. The disadvantagesof this compound are its low stability and low bioavailability. Therefore,carriers for EGCG are sought to increase its use. In this work, newcarriers are proposed, i.e., zeolites containing divalent ions ofmagnesium, calcium, strontium, and zinc in their structure. EGCG isretained on the carrier surface by strong interactions with divalentions. Due to the presence of strong interactions, EGCG is releasedin a controlled manner from the carrier-ion-EGCG drug delivery system.The results obtained in this work confirm the effectiveness of thepreparation of new carriers. EGCG is released from the carriers dependingon the pH; hence, it can be used both in osteoporosis and in the treatmentof cancer. The divalent ion used affects the sorption and releaseof the drug. The obtained results indicate the great potential ofthe proposed carriers and their advantage over the carriers describedin the literature.

Automated summary

This study presents the potential use of zeolites containing divalent ions as carriers for epigallocatechin gallate (EGCG), a compound with high therapeutic potential in osteoporosis and cancer treatment. These new carriers exhibit strong interactions with divalent ions, allowing for controlled release of EGCG from the carrier-ion-EGCG drug delivery system. The results show the effectiveness of these new carriers, and their pH-dependent release of EGCG makes them suitable for both osteoporosis and cancer treatment. The choice of divalent ion used in the carriers affects the drug sorption and release, demonstrating the superiority of the proposed carriers over those described in previous literature.